^
    Back
    Association details:
    Biomarker:FGFR3 R248C
    Cancer:Urothelial Cancer
    Drug:Balversa (erdafitinib) (FGFR inhibitor, FGFR1 inhibitor, FGFR4 inhibitor, FGFR2 inhibitor, FGFR3 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    N Engl J Med
    Title:

    Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

    Excerpt:
    This study met its primary objective, with a 40% confirmed response rate after continuous daily treatment with 8 mg or 9 mg of oral erdafitinib. These findings showed that among patients with locally advanced and unresectable or metastatic urothelial carcinoma with certain FGFR alterations, erdafitinib had promising antitumor activity.
    DOI:
    10.1056/NEJMoa1817323